Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

306
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
306
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

319
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
319
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.0K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.0K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

316
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
316
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Clinical Practice Guideline for the Surgical Management of Ulcerative Colitis.

Diseases of the colon and rectum·2026
Same author

Rethinking Intestinal Stem Cells: Why Fgfbp1 + Progenitors Might Be More Critical Than the Lgr5 + Population.

Diseases of the colon and rectum·2026
Same author

Management and Treatment of Perianal Fistulizing Crohn's Disease.

Clinical and experimental gastroenterology·2025
Same author

Invited commentary on "Functional outcomes of transanal ileal pouch-anal anastomosis in patients with ulcerative colitis: inverse probability weighting analysis of a single-center cohort".

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2025
Same author

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence.

Diseases of the colon and rectum·2025

Related Experiment Video

Updated: Nov 29, 2025

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.4K

Stem cell therapy for perianal Crohn's.

Amy L Lightner1

  • 1Department of Colorectal Surgery, Cleveland Clinic, Ohio, USA.

Current Opinion in Gastroenterology
|November 20, 2020
PubMed
Summary

Mesenchymal stem cells (MSCs) offer a safe and effective treatment for perianal Crohn's disease, outperforming conventional therapies. Further research will optimize MSC protocols and explore acellular regenerative options.

Area of Science:

  • Regenerative Medicine
  • Gastroenterology
  • Immunology

Background:

  • Perianal Crohn's disease presents significant treatment challenges with conventional therapies.
  • Mesenchymal stem cells (MSCs) represent a promising novel therapeutic approach.

Purpose of the Study:

  • To review the current evidence on MSC therapy for perianal Crohn's disease.
  • To identify key areas for future research to optimize MSC treatment efficacy.

Main Methods:

  • Review of clinical trials involving MSC treatment for perianal Crohn's disease.
  • Analysis of safety and efficacy data compared to conventional treatments.

Main Results:

  • Over 300 patients treated with MSCs show consistent safety and superior efficacy to biologics and surgery.

More Related Videos

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model
09:58

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Published on: August 11, 2018

7.8K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.3K

Related Experiment Videos

Last Updated: Nov 29, 2025

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.4K
Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model
09:58

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Published on: August 11, 2018

7.8K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.3K
  • Sustained healing up to one year demonstrated in Phase III trials.
  • Heterogeneity in protocols (dosing, delivery, donor type) did not negate efficacy.

    • Conclusions:

    • MSCs are a safe and effective regenerative therapy for perianal Crohn's disease.
    • Outstanding questions remain regarding optimal MSC source, donor, delivery, and potential alloimmune responses.
    • Future research may focus on optimizing MSCs or exploring acellular regenerative therapies.